In the Prandin case, Faruqi & Faruqi represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Novo Nordisk’s branded diabetes drug Prandin (repaglinide). The case alleges that Novo Nordisk engaged in an overarching anticompetitive scheme to block less-expensive generic Prandin competition and thereby force direct purchasers to pay overcharges for repaglinide. Novo Nordisk’s scheme is alleged to include defrauding the United States Patent and Trademark Office into issuing a particular patent, and purposely manipulating that patent’s “use code narrative” in the FDA Orange Book in a deliberate effort to prevent FDA from approving generic versions of Prandin even for monotherapy, a disclaimed prior art use that did not and could not infringe any Novo Nordisk patent. A violation of § 2 of the Sherman Act is charged. Faruqi & Faruqi, LLP was appointed by the court to serve on the executive committee of this case.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 06/07/2010
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771